Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00831467
Recruitment Status : Completed
First Posted : January 29, 2009
Last Update Posted : March 20, 2018
Information provided by (Responsible Party):
CureVac AG

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : December 2009
  Study Completion Date : September 2013